Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04755283 · ClinicalTrials.gov registry record · Phase 2

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

A Phase 2 study of Stroke and Atrial Fibrillation (AF), sponsored by Anthos Therapeutics.

Active
Registry status
Phase 2
Development phase
1,287
Enrollment target
20
Study locations

NCT04755283 is a Phase 2 study of Stroke and Atrial Fibrillation (AF) that is active but no longer recruiting, run by Anthos Therapeutics. The registered enrollment target is 1,287 participants, below the 12,014-participant average among 454 other Stroke trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04755283, a Phase 2 study of Stroke and Atrial Fibrillation (AF), is active but no longer recruiting, sponsored by Anthos Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
1,287 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.

Conditions Studied

Stroke Atrial Fibrillation (AF)

Interventions

  • BIOLOGICAL Abelacimab
  • DRUG Rivaroxaban

Study Locations (20)

Florida

  • Anthos Investigative Site - Clearwater
  • Anthos Investigative Site - Daytona Beach
  • Anthos Investigative Site - Largo
  • Anthos Investigative Site - Safety Harbor
  • Anthos Investigative Site - Saint Augustine

Alabama

  • Anthos Investigative Site - Huntsville
  • Anthos Investigative Site - Mobile

Maryland

  • Anthos Investigative Site - Baltimore
  • Anthos Investigative Site - Salisbury

Massachusetts

  • Anthos Investigative Site - Framingham
  • Anthos Investigative Site - Haverhill

New York

  • Anthos Investigative Site - Poughkeepsie
  • Anthos Investigative Site - Southampton

Connecticut

  • Anthos Investigative Site - Stamford

Georgia

  • Anthos Investigative Site - Johns Creek

Kentucky

  • Anthos Investigative Site - Owensboro

Trial Details

FieldValue
Enrollment Target 1,287 participants
Start Date 2021-02-02
Est. Completion 2028-12-29
Phase Phase 2

Sponsor

Anthos Therapeutics

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04755283

The ClinicalTrials.gov registry entry for NCT04755283 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 1,287 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,014-participant average among 454 other Stroke trials with a reported enrollment target (89% lower). The listed sponsor is Anthos Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Stroke appearing as the primary indexed condition, and to 2 interventions - of which Abelacimab is the first listed.

NCT04755283 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Alabama, Maryland.

Frequently Asked Questions

What is clinical trial NCT04755283 about?

NCT04755283 is a clinical study titled "Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation". The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.

What is the current status of trial NCT04755283?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1,287 participants. The study started on 2021-02-02. Estimated completion is 2028-12-29.

What conditions does trial NCT04755283 study?

This clinical trial studies the following conditions: Stroke, Atrial Fibrillation (AF).

What interventions are being tested in trial NCT04755283?

The interventions under investigation include: Abelacimab (BIOLOGICAL), Rivaroxaban (DRUG).

Who is sponsoring clinical trial NCT04755283?

This trial is sponsored by Anthos Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04755283 being conducted?

This trial has 20 study locations across Alabama, Connecticut, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stroke

All registered trials for this condition

Atrial Fibrillation (AF)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.